$heff's $tation of $tocks & $olid DD

[nywest329]

LXRX- DD with EOM catalyst


Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting

Press Release: Lexicon Pharmaceuticals, Inc. – 3 hours ago


THE WOODLANDS, Texas, June 8, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012.
Lexicon has completed dosing in a Phase 2b study of LX4211 in 299 patients with type 2 diabetes and expects to report top-line results at the end of June.

http://finance.yahoo.com/news/lexicon-presents-data-regarding-mechanism-220000101.html



Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Trial to Test Oral Therapy for Insulin-Dependent Diabetes


Press Release: Lexicon Pharmaceuticals, Inc. – Thu, May 3, 2012 7:00 AM EDT


THE WOODLANDS, Texas, May 3, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.
LX4211, a dual inhibitor of sodium glucose transporter 1 and 2 (SGLT1 and SGLT2), was designed to improve control of blood glucose through mechanisms that do not require the pancreas to produce insulin. In type 1 diabetes, also called juvenile diabetes, the pancreas stops producing enough insulin to support life. People with type 1 diabetes must monitor their blood sugar levels through frequent measures of blood glucose in order to select and administer doses of insulin via shots or an insulin pump, multiple times every day. With current insulin therapies, even vigilant management of blood sugar does not eliminate the risk of type 1 diabetes complications such as heart attack, stroke, blindness, and kidney failure.
"Results we have obtained to date with LX4211 encourage us to expand its potential application to both type 1 and type 2 diabetes, a unique opportunity for an oral therapy," said Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer. "In this new trial, we hope to see significant reductions in the amount of insulin required by type 1 patients as well as more consistent blood sugar control."
LX4211 has already demonstrated beneficial effects on glucose control in clinical trials conducted to date in type 2 diabetes, or adult-onset diabetes. Studies have shown that LX4211 lowers blood sugar levels after meals, reducing glucose absorption from the gastrointestinal tract and triggering the production of beneficial hormones such as glucagon-like peptide-1 (GLP-1) that help regulate blood glucose levels. In addition, LX4211 enhances excretion of glucose in the urine, which may also help to reduce the need for insulin, without causing low blood sugar or hypoglycemia. Lexicon expects to have results from an ongoing Phase 2b trial in type 2 diabetes by mid-year 2012.
About the Clinical Trial in Type 1 Diabetes
The initial Phase 2 proof-of-concept study will be a randomized, double-blinded, placebo-controlled trial in approximately 25 adult patients with type 1 diabetes who will receive LX4211 over a one month treatment period. The primary endpoint of the study will be reduction of insulin required with LX4211 as compared to placebo. Secondary endpoints will include multiple measures of blood sugar to show that LX4211 helps to maintain glycemic control during the treatment period. Under the agreement, additional funding could support future Phase 2 trials of LX4211 in type 1 diabetes.


http://finance.yahoo.com/q?s=lxrx